VEXAS Syndrome: Somatic UBA1 Mutations, Adult-Onset Hematologic-Rheumatologic Overlap, and Azacitidine to Transplant Therapy
Adult-onset autoinflammatory disorder caused by somatic UBA1 mutations in myeloid precursors — recognized by macrocytic anemia plus systemic inflammation plus characteristic vacuoles in marrow myeloid precursors plus MDS-like clonal hematopoiesis.
Executive Summary
Contents
- Pathophysiology and Discovery
- UBA1 somatic mutation biology
- X-linked male predominance
- Inflammatory cascade activation
- Diagnostic Evaluation
- Clinical phenotype recognition
- Marrow vacuoles morphology
- UBA1 sequencing
- Treatment Strategies
- Corticosteroid bridging
- JAK inhibitors and biologic options
- Azacitidine and stem cell transplantation
- Monitoring and Surveillance
- Clinical Commentary and Referral
- Practice Insights — Synthesized Patterns for VEXAS Care
- Frequently Asked Questions
S1. Pathophysiology and Discovery
VEXAS syndrome was identified in 2020 through unbiased genomic analysis of a cohort of adult men with treatment-refractory inflammatory disease that did not fit established autoimmune or autoinflammatory classifications. The investigators identified shared somatic mutations affecting methionine 41 (the catalytic residue near the active site) of UBA1, the X-linked gene encoding the ubiquitin-activating enzyme E1. UBA1 catalyzes the first step of the ubiquitin-proteasome pathway, activating ubiquitin in an ATP-dependent reaction that prepares the small protein for conjugation to substrates destined for proteasomal degradation. Loss of catalytic UBA1 activity disrupts the ubiquitin-proteasome system in mutated hematopoietic cells, producing accumulation of misfolded and ubiquitin-target proteins, endoplasmic reticulum stress, unfolded protein response activation, and downstream inflammatory cascade triggering through NF-κB and other pathways.
UBA1 is located on the X chromosome and the somatic mutations producing VEXAS occur in hematopoietic stem cells with downstream propagation through the myeloid lineage. The X-linked location of UBA1 explains the striking male predominance of the disorder: men are hemizygous for the X chromosome, so a single mutated UBA1 allele in a hematopoietic stem cell produces a clonal population of UBA1-deficient myeloid cells with no wild-type counterpart in those cells. Women have two X chromosomes and typically retain wild-type UBA1 activity on the non-mutated allele in mutated cells, requiring biallelic involvement or skewed X-inactivation to produce a similar phenotype. The reported female VEXAS cases generally involve monosomy X (Turner syndrome) or extremely skewed X-inactivation that effectively eliminates wild-type UBA1 expression in hematopoietic cells.
The mutations are clustered at methionine 41 (M41V, M41T, M41L as the most common variants accounting for over 90 percent of cases in published cohorts), with other UBA1 mutations producing similar phenotypes. The methionine 41 residue is part of a translation initiation site, and mutations at this position eliminate translation of the predominant cytoplasmic UBA1 isoform while preserving a less abundant nuclear isoform, producing a profound cytoplasmic UBA1 deficiency that disrupts the ubiquitin-proteasome system in myeloid cells. The downstream consequences include accumulation of unfolded proteins triggering endoplasmic reticulum stress, activation of the unfolded protein response, and downstream inflammatory cascade through NF-κB activation, type I interferon signaling, and cytokine storm including IL-6, TNF, and interferons. The clinical phenotype reflects this multi-pathway inflammatory activation.
S2. Diagnostic Evaluation
The diagnostic workflow combines clinical phenotype recognition (the cross-disciplinary hematologic and rheumatologic features in an older man), morphologic confirmation through bone marrow examination showing the characteristic vacuoles, and molecular confirmation by UBA1 sequencing. Recognition is increasing as awareness of the disorder has grown since its 2020 description, but many cases are still being identified retrospectively in patients with longstanding refractory inflammatory disease previously classified as relapsing polychondritis, Sweet syndrome, polyarteritis nodosa, or MDS with autoimmune features.
| Test | VEXAS finding | Practice pearl |
|---|---|---|
| Clinical phenotype | Adult-onset (typically male over 50) refractory inflammation + macrocytic anemia + multi-organ involvement | Diagnostic suspicion most important when fitting historically distinct diagnoses don’t fully explain syndrome |
| CBC with MCV | Macrocytic anemia (MCV typically > 100 fL); thrombocytopenia; lymphopenia in subset | Macrocytic anemia in setting of inflammation is the hematologic anchor |
| Inflammatory markers | Markedly elevated CRP (often > 100 mg/L); ESR elevated | Persistent elevation in patient with diverse organ involvement |
| Ferritin | Often elevated (acute phase plus possible iron overload) | Helps gauge inflammatory burden |
| Bone marrow aspirate + biopsy | Vacuoles in myeloid precursors (promyelocytes) and erythroid precursors in ~80% of cases | Diagnostic clue when present; sensitivity is imperfect but specificity good with clinical context |
| Marrow cytogenetics | Frequently normal; clonal abnormalities in MDS-overlap cases | Documents MDS evolution when present |
| UBA1 sequencing | Somatic mutation at methionine 41 (M41V/M41T/M41L most common) or other locations | Definitive diagnostic test; targeted sequencing from peripheral blood or marrow |
| Skin biopsy of involved lesions | Neutrophilic dermatosis (Sweet syndrome pattern) or other inflammatory infiltrate | Histologic confirmation of skin manifestations |
| Imaging (chest CT) | Pulmonary infiltrates, ground-glass opacities, alveolar hemorrhage | Surveys pulmonary involvement |
| Vascular imaging (CT/MR angiography) | Vasculitis features in subset; VTE evaluation | Pursue with clinical evidence of vascular involvement |
| ANA, ANCA, RF, anti-CCP | Negative or non-specific; supports VEXAS rather than classical autoimmune disease | Negative serology in face of clear inflammation supports VEXAS workup |
| Tryptase, complement, immunoglobulins | Routine connective tissue / autoinflammatory workup | Excludes alternative diagnoses |
The clinical features that should specifically trigger VEXAS workup include: adult-onset (typically over 50) refractory inflammatory disease in a man; macrocytic anemia with MCV above 100 fL; coexisting features that historically span multiple specialty boundaries (rheumatologic-hematologic-dermatologic); poor response to or relapse on tapering of corticosteroids; relapsing polychondritis features with marked inflammatory markers; Sweet syndrome with systemic features; medium-vessel vasculitis with cytopenia; treatment-refractory MDS with inflammatory features; and recurrent venous thromboembolism with inflammation. The clinical pattern essentially crosses the historic specialty borders, and the diagnostic suspicion grows when no single classical diagnosis explains the entire syndrome.
UBA1 sequencing is the definitive diagnostic test, performed from peripheral blood or bone marrow DNA. Targeted Sanger sequencing of the relevant exons or broader next-generation sequencing of myeloid panels including UBA1 can identify the somatic mutations. The variant allele frequency (VAF) of the UBA1 mutation typically ranges from 30 to 80 percent in the myeloid lineage, reflecting the clonal expansion of mutated cells. VAF below 10 percent in peripheral blood may suggest evolving disease or sampling variability. Bone marrow examination demonstrating the characteristic vacuoles in myeloid and erythroid precursors provides the morphologic diagnostic clue that can prompt sequencing when the clinical syndrome is recognized; however, the vacuoles can also be seen in copper deficiency and chronic alcohol use, with specificity coming from the clinical context plus UBA1 mutation confirmation.
S3. Treatment Strategies
Treatment in VEXAS is complex because the disorder bridges autoinflammatory disease (responsive to immunosuppression) and clonal hematopoietic disease (responsive to MDS-directed therapy or transplantation). Corticosteroids produce dramatic clinical response in essentially all patients but with substantial relapse on tapering, leading to chronic steroid dependence and complications. Steroid-sparing strategies include JAK inhibitors (ruxolitinib showing the most efficacy across published case series), IL-6 inhibitors (tocilizumab), and IL-1 inhibitors (anakinra). Clone-directed therapy with hypomethylating agents (azacitidine) targets the underlying clonal substrate. Allogeneic stem cell transplantation is the only curative option but carries substantial transplant-related mortality in the typically older multimorbid VEXAS population.
| Therapy | Indication | Dose | Notes |
|---|---|---|---|
| Prednisone | Bridging therapy and chronic maintenance | 0.5–1 mg/kg/day PO with prolonged taper | Dramatic clinical response; high relapse on taper |
| Methylprednisolone IV pulse | Severe acute flares | 250–1000 mg IV daily × 3 days | Bridge to oral; reserved for severe presentation |
| Ruxolitinib (JAK inhibitor) | Steroid-sparing; emerging first-line steroid-sparing option | 5–20 mg PO BID titrated | Case series support; targets cytokine signaling driving inflammation |
| Tocilizumab | Refractory inflammation; IL-6 dominant phenotype | 162 mg SC weekly or 8 mg/kg IV monthly | IL-6 receptor antagonist; case series support |
| Anakinra | IL-1 inhibition for refractory inflammation | 100 mg SC daily | Short half-life; less established than JAK or IL-6 inhibition |
| Azacitidine | MDS overlap; clone-directed therapy | 75 mg/m² SC daily × 7 days q28 days | Targets clonal hematopoietic substrate; modest response on inflammation |
| Allogeneic stem cell transplantation | Fit patients; curative intent | Per transplant protocol with reduced-intensity conditioning | Only curative option; TRM 20–50% in older multimorbid population |
| Methotrexate | Steroid-sparing with chronic inflammation | 15–25 mg PO/SC weekly + folate | Modest response; less effective than JAK or IL-6 inhibitor monotherapy |
| Cyclosporine, mycophenolate | Alternative steroid-sparing | Per protocol | Case-by-case based on dominant features |
| Anticoagulation | VTE (~30–40% lifetime risk) | DOAC or warfarin per standard VTE protocol | Strongly consider primary prophylaxis given high VTE risk |
| Transfusion support | Symptomatic anemia or thrombocytopenia | Per threshold and symptoms | Chronic transfusion in advanced disease |
| Pneumocystis prophylaxis | Chronic steroid plus immunosuppression | TMP-SMX 80/400 mg PO daily | Essential during sustained immunosuppression |
| Vaccinations | Influenza pneumococcal zoster COVID | Annual flu; pneumococcal per schedule | Update before transplant or biologic initiation |
Corticosteroids remain the cornerstone of acute management because of the dramatic response — essentially all VEXAS patients respond to prednisone at 0.5–1 mg/kg/day with rapid reduction of inflammatory symptoms, fever resolution, and inflammatory marker decline. The challenge is sustained maintenance because steroid tapering below approximately 15–20 mg daily typically produces relapse. Established practice combines prednisone with steroid-sparing biologic therapy (ruxolitinib, tocilizumab, anakinra) to permit lower steroid doses and reduce long-term steroid morbidity. Ruxolitinib has emerged as the most promising steroid-sparing option based on case series demonstrating efficacy across the inflammatory spectrum, with dosing typically 5–20 mg twice daily titrated to clinical response and tolerability.
Clone-directed therapy with hypomethylating agents addresses the underlying clonal hematopoietic substrate. Azacitidine 75 mg/m² subcutaneous daily for 7 days every 28 days is the standard MDS regimen and has been used in VEXAS with MDS overlap and progressive cytopenias, producing modest inflammatory response in addition to hematologic improvement. The therapy is typically combined with anti-inflammatory regimens rather than used as monotherapy. Allogeneic stem cell transplantation is the only currently curative therapy, targeting both the inflammatory and clonal hematologic components by replacing the entire UBA1-mutated hematopoietic system with donor-derived wild-type cells. Transplant-related mortality (20–50 percent) is substantial in the typically older multimorbid VEXAS population, limiting the procedure to younger and fitter candidates. Reduced-intensity conditioning regimens improve tolerability in selected older patients.
S4. Monitoring and Surveillance
Monitoring centers on inflammatory disease activity, steroid taper management, hematologic surveillance for MDS evolution and progression, infection surveillance during immunosuppression, and complication management (VTE, infections, steroid-related morbidity). The chronic relapsing course with high relapse rate on steroid tapering requires ongoing care at 1–3 month intervals indefinitely.
| Phase / Domain | What to monitor | Frequency |
|---|---|---|
| Active disease | Symptom assessment CBC CRP ESR ferritin | Every 2–4 weeks |
| Steroid taper phase | Symptom recurrence CBC inflammatory markers glucose BP | Monthly during taper |
| Stable maintenance | CBC inflammatory markers symptom diary | Every 1–3 months |
| Marrow surveillance | Repeat bone marrow with cytogenetics MDS evolution assessment | Annually or with cytopenia progression |
| UBA1 VAF tracking | Trends in clonal burden | Every 6–12 months (selective) |
| VTE surveillance and prophylaxis | Symptom assessment risk reassessment | Every visit; primary prophylaxis consideration |
| Infection surveillance | PJP prophylaxis vaccination status fungal/viral risk during immunosuppression | Every visit |
| Steroid-related complications | Bone density glucose lipids BP weight | Annual DXA; routine labs |
| Cardiovascular surveillance | BP lipids cardiovascular event monitoring | Per standard cardiovascular risk management |
MDS progression is the long-term hematologic concern. A meaningful fraction of VEXAS patients develop frank myelodysplastic syndrome over follow-up with progressive cytopenias and increased marrow blast percentages. Some progress to acute myeloid leukemia. Surveillance bone marrow examination with cytogenetics and next-generation sequencing of myeloid mutation panels at annual intervals or with significant cytopenia progression identifies MDS evolution and triggers hypomethylating agent therapy or transplant evaluation. VTE risk (approximately 30–40 percent lifetime) is substantial and may justify primary prophylaxis with low-dose anticoagulation in selected patients, with established practice considering this in patients with severe inflammation, prior VTE, or other prothrombotic risk factors.
S5. Clinical Commentary and Referral
VEXAS syndrome is the prototype of a new class of adult-onset autoinflammatory disorders driven by somatic mutations in hematopoietic stem cells. The disorder fundamentally crosses the historic boundaries of rheumatology and hematology and represents the diagnostic challenge of an entity that didn’t have a name until 2020 but explains a meaningful fraction of previously refractory adult inflammatory disease. Established practice has rapidly incorporated UBA1 sequencing into the workup of refractory adult inflammatory disease in men over 50, particularly when hematologic features (macrocytic anemia, MDS features) accompany the rheumatologic presentation.
S6. Practice Insights — Synthesized Patterns for VEXAS Care
What the Guideline Misses
Experienced clinicians have learned that VEXAS is consistently missed when refractory inflammatory disease in older men is diagnosed by its dominant component (relapsing polychondritis Sweet syndrome polyarteritis nodosa) without consideration of the unifying underlying disorder. Established practice considers VEXAS in any treatment-refractory adult inflammatory disease in men over 50 particularly when macrocytic anemia accompanies the inflammatory features.
Patterns That Repeat
Across published case series the cross-specialty boundary nature of VEXAS results in fragmented care when hematology and rheumatology manage component features in isolation. Established practice integrates care through joint clinic models or multidisciplinary VEXAS conferences that coordinate corticosteroid management steroid-sparing biologic decisions clone-directed therapy considerations and transplant evaluation across specialties.
The Bedside Heuristic
Established practice has increasingly adopted ruxolitinib as first-line steroid-sparing therapy in VEXAS based on case series demonstrating efficacy across the inflammatory spectrum. The JAK inhibition targets the cytokine signaling driving the multi-organ inflammation and allows substantial steroid dose reduction in many patients. Tocilizumab and anakinra remain alternatives particularly when IL-6 or IL-1 dominance is suggested by phenotype.
Illustrative Scenario — Retrospectively Recognized VEXAS
A composite scenario from published series describes a man in his late 60s with 4 years of progressive refractory inflammatory disease previously managed under multiple component diagnoses. Initial presentation 4 years prior was relapsing polychondritis with ear cartilage inflammation and treatment response to prednisone followed by relapse on tapering. Two years prior, neutrophilic urticaria appeared with skin biopsy consistent with Sweet syndrome. Eighteen months prior, deep vein thrombosis prompted anticoagulation. Six months prior, progressive macrocytic anemia (Hb 9.4 g/dL, MCV 108 fL) and mild thrombocytopenia (platelets 110 × 10^9/L) prompted bone marrow examination which showed myelodysplastic syndrome with multilineage dysplasia and characteristic vacuoles in myeloid and erythroid precursors. UBA1 sequencing identifies a somatic M41V mutation with variant allele frequency 65 percent in peripheral blood. The diagnosis of VEXAS syndrome reframes the multi-year disease course as a unified entity. Treatment is reorganized: prednisone tapered slowly to 10 mg daily, ruxolitinib initiated at 10 mg twice daily, anticoagulation continued, pneumocystis prophylaxis added, azacitidine added for the MDS component. At 12 months on combination therapy the patient achieves substantial reduction in inflammatory activity and stable hematology with no major flares. Stem cell transplant evaluation is performed but deferred given comorbidity profile and patient preference.
Practice Pattern Refinements
- Order UBA1 sequencing in any adult-onset refractory inflammatory disease in men over 50 particularly when macrocytic anemia (MCV above 100 fL) coexists with the inflammatory features. Established practice integrates UBA1 testing into the workup of treatment-refractory relapsing polychondritis Sweet syndrome polyarteritis nodosa or other adult inflammatory disorders rather than waiting for retrospective recognition after years of fragmented component-diagnosis management.
- Examine bone marrow specifically for cytoplasmic vacuoles in myeloid and erythroid precursors when VEXAS is suspected. The vacuoles are present in approximately 80 percent of cases and provide a morphologic diagnostic clue that prompts UBA1 sequencing. The vacuoles are also seen in copper deficiency and chronic alcohol use so specificity depends on clinical context plus UBA1 mutation confirmation.
- Combine corticosteroids with steroid-sparing biologic from the outset rather than relying on prolonged steroid monotherapy. Ruxolitinib 5–20 mg twice daily titrated to clinical response has emerged as the leading steroid-sparing option based on case series. Tocilizumab and anakinra are alternatives. Combination therapy enables lower sustained prednisone doses and reduced long-term steroid morbidity while maintaining inflammatory control.
- Evaluate fit younger VEXAS patients for allogeneic stem cell transplantation as the only currently curative therapy. Transplant-related mortality is substantial (20–50 percent) in the typically older multimorbid population but is the only option offering cure of both the inflammatory and clonal hematologic components. Reduced-intensity conditioning regimens improve tolerability in selected older fit patients and expand transplant eligibility compared with full-intensity protocols.
S7. Frequently Asked Questions
What is VEXAS syndrome?
Why is VEXAS predominantly in men?
How is VEXAS diagnosed?
What is the role of ruxolitinib?
What is the prognosis?
Is stem cell transplantation curative?
Can VEXAS be inherited?
- Polymyalgia Rheumatica: Diagnosis, GCA Overlap, Glucocorticoid Therapy, and Steroid-Sparing Strategies
- Ankylosing Spondylitis: ASAS Classification, Imaging, and Biologic Therapy Pathways
- Granulomatosis with Polyangiitis: ANCA Diagnosis, Induction Cyclophosphamide vs Rituximab, and Maintenance Therapy
- Systemic Sclerosis (Scleroderma): Classification, Organ Involvement, and Disease-Modifying Therapy
- Giant Cell Arteritis: Diagnosis, Imaging, and Tocilizumab-Sparing Therapy
- Gout: ACR 2020 Management, Urate-Lowering Therapy, and Flare Control